Company Overview

Universal Ibogaine Inc. (OTC: IBOGF) is a publicly traded healthcare services company focused on addiction treatment utilizing ibogaine-assisted therapy. The company operates within the addiction treatment, behavioral health, and alternative mental health services industries, targeting substance use disorders that have proven resistant to conventional therapies. Its core offering centers on medically supervised ibogaine treatment programs, which are positioned as an alternative approach for opioid and other substance dependencies. Available public disclosures indicate that the company primarily serves patients seeking intensive residential treatment, rather than institutional healthcare providers or insurers.

The company was founded in Canada and evolved from a development-stage enterprise into a treatment-focused operator as regulatory constraints in Canada limited domestic ibogaine use. To address this, Universal Ibogaine shifted its operational model to jurisdictions where ibogaine treatment is permitted, most notably Mexico. This strategic pivot has defined the company’s business model and geographic orientation. Public filings and market disclosures show limited revenue scale and an early-stage operational profile, with the company emphasizing proof-of-concept treatment outcomes and clinical protocols rather than broad commercial expansion.

Business Operations

Universal Ibogaine generates revenue primarily through patient treatment fees associated with its ibogaine-assisted addiction recovery programs. Operations are conducted through a controlled clinical setting that integrates medical screening, monitored dosing, and post-treatment support. The company does not manufacture ibogaine at scale; instead, its value proposition is centered on clinical oversight, safety protocols, and treatment program design. Based on public disclosures, the company’s operating activities are concentrated in a single primary treatment location rather than a diversified network of facilities.

Internationally, the company conducts treatment operations outside of Canada due to regulatory limitations. Public information indicates that these activities are carried out through a wholly owned operating entity in Mexico; however, the specific legal subsidiary structure and asset ownership details are not consistently disclosed across filings. There is no verified evidence of material joint ventures, pharmaceutical partnerships, or licensed technology platforms beyond internally developed clinical protocols. Data inconclusive based on available public sources regarding proprietary technologies or exclusive supplier arrangements.

Strategic Position & Investments

Strategically, Universal Ibogaine positions itself as a niche provider within the emerging field of psychedelic-assisted and alternative addiction therapies, with a near-term focus on operational execution rather than large-scale acquisitions. The company’s stated growth initiatives emphasize refining treatment protocols, improving patient safety metrics, and increasing treatment capacity within existing regulatory frameworks. Unlike larger peers in the psychedelic sector, Universal Ibogaine has not disclosed material investments in drug development pipelines or late-stage clinical trials.

Public filings do not show evidence of significant acquisitions, minority investments, or a diversified subsidiary portfolio. The company’s strategic emphasis remains on ibogaine-assisted therapy rather than expansion into adjacent psychedelics or mental health modalities. While ibogaine is often discussed within the broader psychedelic sector, the company’s involvement is service-based rather than pharmaceutical. Data inconclusive based on available public sources regarding future expansion into regulated drug development or institutional healthcare partnerships.

Geographic Footprint

Universal Ibogaine is headquartered in Canada, with corporate oversight and public company administration conducted domestically. Operational treatment activities are primarily located in Mexico, where ibogaine treatment is legally permissible under certain conditions. This cross-border structure defines the company’s operational footprint and regulatory exposure.

The company does not report material operations in the United States, Europe, or other international markets beyond Mexico. Its geographic presence is therefore limited, with influence concentrated in North America through patient inflows rather than physical facilities. There is no verified disclosure of international investment holdings, satellite clinics, or expansion projects across other continents.

Leadership & Governance

Universal Ibogaine was founded by individuals involved in addiction recovery advocacy and early-stage healthcare entrepreneurship, though founder roles have evolved as the company transitioned to public markets. Leadership communications emphasize patient safety, medical oversight, and responsible operation within existing legal frameworks rather than rapid commercialization. Governance follows standard public company practices for OTC-listed issuers, with a small executive team and board structure.

Key executives publicly identified include:

• Nick Karos – Chief Executive Officer
• Nick Karos – Director

Additional executive officers, independent directors, or clinical leadership roles are not consistently disclosed across public filings. Data inconclusive based on available public sources regarding the full executive team composition and board independence structure.